STORM Therapeutics Joins SMi’s 9th Annual RNA Therapeutics
Oliver has overall responsibility for developing STORM’s target discovery platform and for the delivery of small molecule drugs from its emerging drug discovery pipeline. Oliver worked closely with scientific founders Professors Tony Kouzarides and Eric Miska to secure the initial £12m series; an investment that launched STORM and subsequently joined the company full time in October 2016.
Prior to STORM, Oliver was Programme Director at the National Institute for Health Research (NIHR), where he led the Translational Research Partnerships (TRPs) initiative and other industry-focused collaboration programmes in experimental medicine and early drug development. He served as Vice President Biology at Cellzome until the company’s acquisition by GSK in 2012, and as Director of Biology at UCB Pharma until 2008.
SMi are excited to have interviewed Oliver about his talk and career experience.
Below is a snapshot of his interview:
Q. What do you see as the greatest challenge for those trying to develop RNA Therapeutics?
A. Delivery of the therapeutic molecules to the appropriate target tissues – there are limitations for RNA therapies which we are trying to overcome through a small molecule approach.
Q. What is the most exciting project that you have worked on during your career and why?
A. The project of setting up and launching Storm Therapeutics, establishing a drug discovery organisation in a completely untapped field of biology.
Q. Are there any dangers associated with the use of RNA modifying enzymes?
Check out the full interview, available in the download centre.
Hear more from Oliver Rausch at RNA Therapeutics this February 2018, as he presents 'Harnessing the Power of RNA Epigenetics - Targeting RNA Modifying Enzymes for the Treatment of Cancer.' www.therapeutics-rna.com/opr
Topics will explore:
- Over 150 different chemical modifications have been identified on RNA molecules.
- The role of these modifications in the maturation and regulation of coding and non-coding RNA is becoming increasingly prominent.
- Utilising the research of world-leading founders Professors Kouzarides and Miska in the field of RNA epigenetics to pioneer the development of small molecule inhibitors of previously untargeted RNA-modifying enzymes (RMEs) to interfere with key RNA pathways and mechanisms.
More About Oliver Rausch:
Oliver has over 15 years’ drug discovery experience in inflammation, neurology and oncology. He holds a degree in Biochemistry from the Free University Berlin and a PhD in Biochemistry and Cell Biology from the Institute of Cancer Research in London.
Further information is available at: www.therapeutics-rna.com/opr
SMi presents the 9th Annual Conference:
Date: 21st – 22nd February 2018
Location: Holiday Inn London - Kensington Forum
Sponsored by: ChemGenes | Phion Therapeutics | Advanced Cell Diagnostics | Lypocalyx
For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: email@example.com
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Westminster Bridge Road
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release STORM Therapeutics Joins SMi’s 9th Annual RNA Therapeutics here
News-ID: 856447 • Views: 289
More Releases from SMi Group
Registration is now open for Pre-filled Syringes San Francisco Conference 2021
SMi Reports: Registration has opened for the 2nd annual Pre-Filled Syringes San Francisco taking place on 13th – 14th September. As part of SMi’s leading Injectables series, this year’s event will address the key drivers of the pre-filled syringes and combination products industry to give a comprehensive insight into the latest device innovations, regulatory updates and future insights for the coming year. Visit the event website to learn more and download
How a hard Brexit will impact the EU market and the effects of Parallel Trade pr …
SMi Reports: Exploring the challenges, practices and drivers in the aftermath of the transition for Parallel Trade. Join us at SMi’s 15th annual Parallel Trade Conference bringing together industry experts from leading experts to discuss the challenges and drivers of the industry, including the EU regulatory landscape and the impact of the FMD. Collaborate and share ideas of how a hard Brexit will impact the EU market and the effects of Parallel
Registration closing soon for SMi Group’s 14th Annual Border Security Conferen …
SMi Group reports: The Border Security conference hosted by SMi Group is taking place virtually in less than two weeks’ time. SMi Group's 14th annual Border Security conference will be closing in less than two weeks' time. For those interested in attending, important information about the event as well as the preliminary attendee list is released below. Registration is FREE for military and government personnel, and just £499 for commercial
Medical Logistic Experts to present at Defence Logistics Central and Eastern Eur …
SMi Group reports: Senior representatives from the Czech Republic MoD and Austrian Armed Forces are set to present on medical logistics at the virtual event next March During the COVID-19 response, those tasked with maintaining complex medical services have also put in long hours and adapted to changing mission requirements to support patients all over the world. This includes Army medical logisticians who fill critical roles ranging from transporting medicine and
More Releases for RNA
Global RNA Analysis/Transcriptomics Market Report
The Global RNA Analysis / Transcriptomics Market is projected to expand at a CAGR of 12.5% during the forecast period, to hit USD 8.1 Billion by 2026, according to a recent market report compiled by Global Market Estimates. Due to the rising need for personalized medicines, the demand for RNA Analysis / Transcriptomics is expected to raise the market demand. Browse 156 Market Data Tables and 112 Figures spread through 175
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year. Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved
Automated DNA/RNA Isolation System Market Overview Till 2018-2023
Future Market Reports on Global Automated DNA/RNA Isolation System 2018 Research Report presents a professional and complete analysis of on the current Industry situation. The Global report includes Automated DNA/RNA Isolation System Revenue, market Share, industry volume, Trends, Growth aspects. It analyses the important factors of the based on present industry situations, demands, business strategies utilized by Automated DNA/RNA Isolation System market players and the future prospects from various angles
RNA Sequencing: Technologies and Analyses of Global Market Trends
"The Latest Research Report RNA Sequencing: Technologies and Global Markets provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" The global RNA-Sequencing market reached nearly $1.1 billion in 2015, and should reach $1.2 billion in 2016 and $2.1 billion in 2020, registering a compound annual growth rate (CAGR) of 14.9%. The tools and reagents segment should reach over $1.0 billion in 2020 from $566.8
Topics Presented this February 2018 at RNA Therapeutics
SMi’s RNA Therapeutics will be bringing a global presence from MHRA, The RNA Institute, MiNA Therapeutics, AstraZeneca R&D, GSK, Sanofi, CureVac and more. With an agenda full of exciting and new approaches, examine the latest developments in delivery systems for RNA Therapeutics, including Exosomes, Nanocomplexes and Platform Delivery Approaches and patenting RNA Therapeutics. www.therapeutics-rna.com/opr Spotlight: Want to learn about exploiting exosomes for therapeutic use in patients with cystic fibrosis? Have questions answered during
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018! Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led